Solidified self-nanoemulsifying formulation for oral delivery of combinatorial therapeutic regimen: Part II in vivo pharmacokinetics, antitumor efficacy and hepatotoxicity

Pharmaceutical Research

Volumn 31, Issue 4, 2014, Pages 946-958

  Jain, Amit K ^a   Thanki, Kaushik ^a   Jain, Sanyog ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

DMBA induced breast tumor; hepatotoxicity; quercetin; SNEDDS; tamoxifen

Indexed keywords

AEROSIL; DIMETHYLBENZ[A]ANTHRACENE; GELATINASE A; GELATINASE B; QUERCETIN; TAMOXIFEN; TAMOXIFEN CITRATE; ANTINEOPLASTIC AGENT; EMULSIFYING AGENT; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FREEZE DRYING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; NANOEMULSION; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; COMBINATORIAL CHEMISTRY; DRUG EFFECTS; LIVER; MCF 7 CELL LINE; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROCEDURES; RANDOMIZATION; SPRAGUE DAWLEY RAT; TOXICITY;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DELIVERY SYSTEMS; EMULSIFYING AGENTS; FEMALE; HUMANS; LIVER; MCF-7 CELLS; NANOPARTICLES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN;

EID: 84896999556     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1214-1     Document Type: Article

References (46)

1. Jain AK, Thanki K, Jain S. Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral Bioavailability, antitumor efficacy, and drug-Induced toxicity. Mol Pharmaceutics. 2013. doi: 10.1021/mp400311j.
2. Thanki K, Gangawal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: challenges and opportunities. J Control Rel. 2013;170(1):15-40.
3. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2(3):205-13.
4. Jain AK, Swarnakar NK, Godugu C, Singh RP, Jain S. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials. 2012;32(2):503-15.
5. Lettéron P, Labbe G, Degott C, Berson A, Fromenty B, Delaforge M, et al. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice: evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant. Biochem Pharmacol. 1990;39(12):2027-34.
6. McVie JG, Simonetti GP, Stevenson D, Briggs RJ, Guelen PJ, de Vos D. The bioavailability of Tamoplex (tamoxifen). Part 1. A pilot study. Methods Find Exp Clin Pharmacol. 1986;8(8):505-12.
7. Tukker JJ, Blankenstein MA, Nortier JW. Comparison of bioavailability in man of tamoxifen after oral and rectal administration. J Pharm Pharmacol. 1986;38(12):888-92.
8. Middleton E, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000;52(4):673-751.
9. Boots AW, Haenen G, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008;585(2-3):325-37.
10. Piantelli M, Maggiano N, Ricci R, Larocca LM, Capelli A, Scambia G, et al. Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells. J Invest Dermatol. 1995;105(2):248-53.
11. Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M, et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer. 2000;87(4):595-600.
12. Sartippour MR, Pietras R, Marquez-Garban DC, Chen HW, Heber D, Henning SM, et al. The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis. 2006;27(12):2424-33.
13. Ma ZS, Thanh HOAH, Chee Pang NG, Phuc Tien DO, Thanh HN, Hung H. Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifen-quercetin treatment is associated with inhibition of angiogenesis and cellular proliferation. Int J Oncol. 2004;24(5):1297-304.
14. Brookes PS, Digerness SB, Parks DA, Darley-Usmar V. Mitochondrial function in response to cardiac ischemia-reperfusion after oral treatment with quercetin. Free Radic Biol Med. 2002;32(11):1220-8.
15. Liu S, Hou W, Yao P, Li N, Zhang B, Hao L, et al. Heme oxygenase-1 mediates the protective role of quercetin against ethanol-induced rat hepatocytes oxidative damage. Toxicol In Vitro. 2012;26(1):74-80.
16. Gupta C, Vikram A, Tripathi DN, Ramarao P, Jena GB. Antioxidant and antimutagenic effect of quercetin against DEN induced hepatotoxicity in rat. Phytother Res. 2010;24(1):119-28.
17. Abo-Salem OM, Abd-Ellah MF, Ghonaim MM. Hepatoprotective activity of quercetin against acrylonitrile induced hepatotoxicity in rats. J Biochem Mol Toxicol. 2011;25(6):386-92.
18. Tabassum H, Parvez S, Rehman H, Banerjee BD, Raisuddin S. Catechin as an antioxidant in liver mitochondrial toxicity: inhibition of tamoxifen induced protein oxidation and lipid peroxidation. J Biochem Mol Toxicol. 2007;21(3):110-7.
19. Granado-Serrano AB, Martin MA, Bravo L, Goya L, Ramos S. Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). J Nutr. 2006;136(11):2715-21.
20. Caltagirone S, Ranelletti FO, Rinelli A, Maggiano N, Colasante A, Musiani P, et al. Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer. Am J Respir Cell Mol Biol. 1997;17(1):51-9.
21. Ma ZS, Huynh TH, Ng CP, Do PT, Nguyen TH, Huynh H. Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifen-quercetin treatment is associated with inhibition of angiogenesis and cellular proliferation. Int J Oncol. 2004;24(5):1297-304.
22. Lama G, Angelucci C, Bruzzese N, Nori SL, D'Atri S, Turriziani M, et al. Sensitivity of human melanoma cells to oestrogens, tamoxifen and quercetin: is there any relationship with type I and II oestrogen binding site expression? Melanoma Res. 1998;8(4):313-22.
23. Date AA, Nagarsenker MS, Patere S, Dhawan V, Gude RP, Hassan PA, et al. Lecithin-based novel cationic nanocarriers (Leciplex) II: improving therapeutic efficacy of quercetin on oral administration. Mol Pharmaceutics. 2011;8(3):716-26.
24. Jain S, Jain AK, Pohekar M, Thanki K. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: implications on drug induced cardiotoxicity and nephrotoxicity. Free Radic Biol Med. 2013;65C:117-30.
25. Zhigaltsev IV, Maurer N, Akhong Q-F, Leone R, Leng E, Wang J, et al. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Rel. 2005;104(1):103-11.
26. Bayne WF, Mayer LD, Swenson CE. Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. J Pharm Sci. 2009;98(7):2540-8.
27. Misra R, Sahoo SK. Coformulation of doxorubicin and curcumin in poly (D, L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharmaceutics. 2011;8(3):852-66.
28. Acharya S, Sahoo SK. Sustained targeting of Bcr-Abl+ leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy. Biomaterials. 2011;32(24):5643-62.
29. Zhang L, Radovic-Moreno AF, Alexis F, Gu FX, Basto PA, Bagalkot V, et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. Chemmedchem. 2007;2(9):1268-71.
30. Song XR, Cai Z, Zheng Y, He G, Cui FY, Gong DQ, et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci. 2009;37(3):300-5.
31. Lammers T, Subr V, Ulbrich K, Peschke P, Huber PE, Hennink WE, et al. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials. 2009;30(20):3466-75.
32. Krakovičová H, Etrych T, Ulbrich K. HPMA-based polymer conjugates with drug combination. Eur J Pharm Sci. 2009;37(3):405-12.
33. Chen AM, Zhang M, Wei D, Stueber D, Taratula O, Minko T, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small. 2009;5(23):2673-7.
34. Kaneshiro TL, Lu Z-R. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials. 2009;30(29):5660-6.
35. Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev. 1997;25(1):47-58.
36. Neslihan Gursoy R, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004;58(3):173-82.
37. Tang B, Cheng G, Gu JC, Xu CH. Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms. Drug Discov Today. 2008;13(13):606-12.
38. Jain S, Chauhan DS, Jain AK, Swarnakar NK, Harde H, Mahajan RR, et al. Stabilization of the nanodrug delivery systems by lyophilization using universal step-wise freeze drying cycle. Indian Patent Application No 2559/DEL/2011 filed on September 06, 2011.
39. Swarnakar NK, Thanki K, Jain S. Effect of co-administration of CoQ10-loaded nanoparticles on the efficacy and cardiotoxicity of doxorubicin-loaded nanoparticles. RSC Adv. 2013;3:14671-85.
40. Jain AK, Swarnakar NK, Das M, Godugu C, Singh RP, Rao PR, et al. Augmented anticancer efficacy of doxorubicin loaded polymeric nanoparticles after oral administration in breast cancer induced animal model. Mol Pharm. 2011;8(4):1140-51.
41. Chung SY, Sung MK, Kim NH, Jang JO, Go EJ, Lee HJ. Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch Pharm Res. 2005;28(7):823-8.
42. Shin SC, Choi JS, Li X. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm. 2006;313(1):144-9.
43. Bachynsky MO, Shah NH, Patel CI, Malick AW. Factors affecting the efficiency of a self-emulsifying oral delivery system. Drug Dev Ind Pharm. 1997;23(8):809-16.
44. Oliver G, Alitalo K. The lymphatic vasculature: recent progress and paradigms. Annu Rev Cell Dev Biol. 2005;21:457-83.
45. Nilsson UW, Dabrosin C. Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo. Cancer Res. 2006;66(9):4789-94.
46. Tan W-F, Lin L-P, Li M-H, Zhang Y-X, Tong Y-G, Xiao D, et al. Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential. Eur J Pharmacol. 2003;459(2):255-62.